A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
- Disease/Condition
- AML
- Drug/Device/Intervention
- CLAG
- Study type
- Observational
- Intervention type
- combination product
- Primary sponsor
- Nanfang Hospital, Southern Medical University
- Location
- Guanzhou,Guanzhou, China
- Phase
- N/A
- Start date
- Jul 02, 2023
- End date
- Dec 20, 2027
- Enrollment
- 137 participants
Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction failure
Most of patients with acute myeloid leukemia achieved complete remission (CR) after primary
 induction chemotherapy, there were 20-30% patients without CR after first-induction. It was
 uncertain how to treat these patients. It was investigated in our study that these patients
 were re-induced with CLAG Regimen. The CR ratio, overall survival (OS) and relapsed-free
 survival (RFS) was statistically analysed in these patients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05875649
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05875649 through Pure Global AI's free database. This phase not specified trial is sponsored by Nanfang Hospital, Southern Medical University and is currently Not yet recruiting. The study focuses on AML. Target enrollment is 137 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.